REG - CRISM Therapeutics - Notice of AGM and EMI Option Plan

CRISM TherapeuticsAnnouncement

04/08/2025 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250804:nRSD9183Ta&default-theme=true

RNS Number : 9183T  CRISM Therapeutics Corporation  04 August 2025

 

4 August 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Notice of AGM and EMI Option Plan

CRISM Therapeutics Corporation (AIM:CRTX) confirms that the Annual General
Meeting ("AGM") will take place at 11:00am on Tuesday 26 August 2025 at the
offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT.
 Further details are set out in the Notice of AGM, which has been posted to
shareholders today.

 

A copy Notice of AGM can be accessed from the Company´s website at:

https://www.crismtherapeutics.com/documents-and-notices
(https://www.crismtherapeutics.com/documents-and-notices)

 

EMI Option Plan

 

Included within the Notice of AGM is a resolution for a proposed Enterprise
Management Incentives Option Plan (the "EMI Option Plan"). The EMI Option Plan
is intended to be used to help recruit, retain and incentivise key talent and
align employee and shareholder interests by providing eligible employees with
the opportunity to acquire ordinary shares in CRISM at a fixed price. There
are also schedules to the EMI Option Plan which enable the Company to grant
non-tax favoured unapproved options to certain people who are engaged by the
Group, including advisors, consultants and non-executive directors, but who
would not be eligible to receive tax-favoured EMI options under the EMI Option
Plan.

 

Options under the EMI Option Plan would vest in three equal portions over a
two-year period and be exercisable on the second anniversary of their vesting.
The exercise price is expected to be the closing price of the underlying
shares on the day prior to the grant, as may be agreed with HMRC from time to
time. Options would lapse after 10 years. The total of options granted under
the EMI Option Plan will be limited to a maximum of 10% of the Company's
issued share capital.

 

All directors are eligible to receive options in the Company under the EMI
Option Plan, which is considered a related party transaction pursuant to Rule
13 of the AIM Rules for Companies. The Company's Nominated Adviser, SP Angel
Corporate Finance LLP, considers the terms of the EMI Option Plan and director
eligibility to receive options pursuant to the EMI Option Plan to be fair and
reasonable insofar as CRISM's shareholders are concerned.

 

 

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPKQBQABKDNFK